Company Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform.
It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression.
The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders.
In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases.
It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London.
The company was incorporated in 2012 and is based in Singapore.
Country | SG |
IPO Date | Nov 11, 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 266 |
CEO | Dr. Paul B. Bolno M.B.A., M.D. |
Contact Details
Address: Marina One East Tower Singapore, SG | |
Website | https://www.wavelifesciences.com |
Stock Details
Ticker Symbol | WVE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001631574 |
CUSIP Number | Y95308105 |
ISIN Number | SG9999014716 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Paul B. Bolno M.B.A., M.D. | President, Chief Executive Officer & Director |
Dr. Chandra Vargeese Ph.D. | Chief Technology Officer |
Kyle B. Moran CFA | Chief Financial Officer & Principal Accounting Officer |
Anne-Marie Li-Kwai-Cheung | Chief Development Officer |
Daryn Lewis | Senior Vice President & Head of Human Resources |
Dr. Christopher Francis Ph.D. | Senior Vice President of Corporate Development & Head of Emerging Areas |
Dr. Erik Ingelsson M.D., Ph.D. | Chief Scientific Officer |
Dr. Sridhar Vaddeboina Ph.D. | Senior Vice President of Chemistry, Manufacturing & Controls |
Kate Rausch | Head of Investor Relations |
Linda Rockett J.D. | Senior Vice President & General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 27, 2024 | 4 | Filing |
Nov 20, 2024 | 8-K | Current Report |
Nov 15, 2024 | 4 | Filing |
Nov 13, 2024 | 4 | Filing |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | S-8 | Filing |
Nov 12, 2024 | S-8 | Filing |
Nov 12, 2024 | S-3ASR | Automatic shelf registration statement of securiti... |
Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |